- 130.6k views
Medical management of GI Neuroendocrine tumor
The medical management of gastrointestinal neuroendocrine tumors (GI NETs) involves a comprehensive approach tailored to the specific characteristics of the tumor and the individual patient. For well-differentiated, low-grade tumors that exhibit hormone hypersecretion, somatostatin analogs such as octreotide and lanreotide are commonly used. These agents help control symptoms related to excess hormone production and may also exert antiproliferative effects. Targeted therapies play a significant role in the management of advanced GI NETs. Everolimus, an mTOR inhibitor, and sunitinib, a tyrosine kinase inhibitor, are often employed to inhibit pathways involved in tumor growth and angiogenesis. Peptide receptor radionuclide therapy (PRRT), using radiolabeled somatostatin analogs such as lutetium-177 DOTATATE, has shown efficacy in slowing tumor progression and providing symptom relief.
About the Speaker
Dr. Mohanad Diab
Consultant Medical Oncologist, Burjeel Hospital, AUH
Upcoming Case Discussions
Acne: Disorders and Treatment Approaches
Acne is a common dermatological condition caused by clogged pores, excess sebum production, bacterial growth, and inflammation. It can manifest as blackheads, whiteheads, papules, pustules, or cysts, often leading to scarring if untreated. Various factors, including hormonal changes, diet, stress, and genetics, influence its severity. Treatment approaches range from topical and oral medications, such as retinoids, antibiotics, and hormonal therapy, to advanced procedures like chemical peels and laser therapy. A personalized skincare regimen, along with lifestyle modifications, plays a crucial role in managing and preventing acne.
Molecular and Genetic studies in Gynaecological Malignancies
Molecular and genetic studies in gynecological malignancies have revolutionized diagnostics, prognostics, and targeted therapies. Advances in genomic sequencing have identified key mutations in ovarian (BRCA1/2, TP53), endometrial (PTEN, MSI), and cervical cancers (HPV integration, PIK3CA). These findings aid in precision medicine, guiding individualized treatments like PARP inhibitors for BRCA-mutated ovarian cancer. Epigenetic modifications, including DNA methylation and miRNA regulation, further influence tumor progression and therapeutic response. Emerging technologies like liquid biopsies and multi-omics approaches enhance early detection and monitoring. Understanding these molecular pathways is crucial for developing novel therapies and improving survival outcomes in gynecological malignancies.
AI in Enhancing Emergency Care
AI is revolutionizing emergency care by enabling faster, more accurate decision-making. It helps triage patients efficiently, analyze medical data in real-time, and predict outcomes based on historical data, which can prioritize critical cases. AI-powered tools, like diagnostic imaging analysis and predictive algorithms, assist doctors in identifying conditions such as strokes or heart attacks earlier, improving survival rates. Additionally, AI enhances resource allocation and staff management in emergency departments, optimizing response times and reducing workload for healthcare providers.
Management of Postoperative Pain: Best Practices for GP’s
Effective management of postoperative pain is crucial for promoting recovery and preventing complications. General practitioners should start by assessing pain severity using appropriate scales, then tailor the treatment plan based on the patient's medical history and the type of surgery. A combination of pharmacological approaches, such as non-opioid analgesics (e.g., NSAIDs) and opioids when necessary, should be used to minimize pain while reducing the risk of addiction. Multimodal strategies, including physical therapy and non-pharmacological techniques like cold therapy or mindfulness, can further enhance pain relief. Close follow-up is essential to adjust the treatment as needed and ensure the patient's pain is well-controlled.
Author Post
Impact
+
Talks
+
webinar
+
no.of registrations
One liner about speaker
Why is speaker relevant?
Dr. Mohanad Diab's Talks on Assimilate
- 0
The medical management of gastrointestinal neuroendocrine tumors (GI NETs) involves a comprehensive approach tailored to the specific characteristics of the tumor and the individual patient. For well-differentiated, low-grade tumors that exhibit hormone hypersecretion, somatostatin analogs such as octreotide and lanreotide are commonly used. These agents help control symptoms related to excess hormone production and may also exert antiproliferative effects. Targeted therapies play a significant role in the management of advanced GI NETs. Everolimus, an mTOR inhibitor, and sunitinib, a tyrosine kinase inhibitor, are often employed to inhibit pathways involved in tumor growth and angiogenesis. Peptide receptor radionuclide therapy (PRRT), using radiolabeled somatostatin analogs such as lutetium-177 DOTATATE, has shown efficacy in slowing tumor progression and providing symptom relief.